WHO Pharmaceuticals Newsletter 1998, No. 09&10
(1998; 23 pages)
Table des matières
Fermer ce répertoireRegulatory decisions
Afficher le documentAlbumin (human) B batches withdrawn: increase in aluminium level: Austria
Afficher le documentAstemizole - warning concerning arrhythmias: Brazil
Afficher le documentChlormezanone - withdrawn: Zimbabwe
Afficher le documentChlorzoxazone - warning: hepatotoxicity: Chile
Afficher le documentCidofovir - adverse reactions: nephrotoxicity, uveitis/iritis and hearing loss: Gilead Sciences, USA
Afficher le documentFenfluramine and dexfenfluramine - temporary suspension: Brazil
Afficher le documentFenfluramine and dexfenfluramine - warning concerning adverse reactions: Chile
Afficher le documentIonic contrast media - notice of withdrawal: Germany
Afficher le documentLaxatives containing aloe, bisacodyl, cascara sagrada and senna - proposed reclassification: USA
Afficher le documentMeloxicam - data sheet revised: gastrointestinal and skin reactions: UK
Afficher le documentMetamizole sodium - withdrawn due to agranulocytosis: Zimbabwe
Afficher le documentMibefradil - suspended: Germany
Afficher le documentNifedipine - re-approved in myocardial infarction: New Zealand
Afficher le documentPsorial ointment - sales prohibited: undeclared cortisone ingredients: Sweden
Afficher le documentPsorigon cream & lotion - withdrawn: undeclared cortisone ingredients: Germany, USA
Afficher le documentTiclopidine - revised data sheet: thrombotic thrombocytopenic purpura: Roche, USA
Afficher le documentTroglitazone - revised instructions for use: Parke-Davis, USA
Afficher le documentVitamin A and betacarotene - labelling claim prohibited: USA
Ouvrir ce répertoire et afficher son contenuDrug surveillance
Ouvrir ce répertoire et afficher son contenuNew developments
Ouvrir ce répertoire et afficher son contenuMedical devices
Ouvrir ce répertoire et afficher son contenuGeneral information
Ouvrir ce répertoire et afficher son contenuMedication errors
Ouvrir ce répertoire et afficher son contenuVeterinary medicine
 

Astemizole - warning concerning arrhythmias: Brazil

Brazil. The Secretária de Vigilância Sanitária has issued a warning concerning the possibility of arrhythmias occurring in patients taking astemizole, especially at dosages higher than the recommended maximum. The product information has been revised to include this warning. These reactions have been observed when other medicines, such as antihypertensives (mibefradil) and antibiotics (clarithromycin and troleandomycin), have been used concomitantly with astemizole.

Adverse reactions have also been associated with the concomitant use of astemizole with other medicines, such as HIV protease inhibitors (indinavir, ritonavir, saquinavir and nelfinavir), serotonin inhibitors (fluoxetine, fluvoxamine, sertraline, nefazodone and paroxetine), and the antiasthmatic zileuton. Grapefruit juice also interferes with the metabolism of astemizole.

Patients with hepatic disease should not take astemizole.

[See also Pharmaceuticals Newsletter Nos. 1&2, 3&4, 7&8, 1998 and 9&10, 1997]

Reference: Alerta Sanitário! No. 1/98, Secretária de Vigilância Sanitária, Ministry of Health, Brasilia.
[http://svs.saude.gov.br/alerta/alerta1.htm]

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013